Lineage Cell Therapeutics (LCTX) Current Leases (2014 - 2026)

Lineage Cell Therapeutics' Current Leases history runs 13 years deep, the most recent figure standing at $833000.0 for Q1 2026.

• In Q1 2026, Current Leases fell 25.89% year-over-year to $833000.0; the TTM figure through Mar 2026 stood at $833000.0 (down 25.89% YoY), while the FY2025 annual figure was $816000.0, up 1383.64% from the prior year.
• Current Leases for Q1 2026 stood at $833000.0, up from $816000.0 in the prior quarter.
• The five-year high for Current Leases was $1.1 million in Q1 2025, with the low at $31000.0 in Q1 2022.
• The 5-year median for Current Leases is $816000.0 (2025), against an average of $573941.2.
• The sharpest annual moves came in 2022 and 2023: Current Leases sank 96.06% in 2022, then jumped 2841.94% in 2023.
• Lineage Cell Therapeutics' Current Leases stood at $36000.0 in 2022, then surged by 2205.56% to $830000.0 in 2023, then plunged by 93.37% to $55000.0 in 2024, then jumped by 1383.64% to $816000.0 in 2025, then grew by 2.08% to $833000.0 in 2026.
• Business Quant data shows LCTX's Current Leases at $833000.0 in Q1 2026, $816000.0 in Q4 2025, and $1.0 million in Q3 2025.